Opening lecture: the DAIDS research agenda for HIV and related infections (not available)
E. Erbelding
Population PK-PD analysis of 400mg vs. 600mg efavirenz (EFV) once daily in treatment-naïve HIV patients at 48 weeks: results of the ENCORE1 study
L. Dickinson
Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients.
J. Molto
Reduced artemether-lumefantrine exposure in HIV-infected Nigerian subjects on nevirapine-based antiretroviral therapy
K. Scarsi
Development of long-acting ARVs and broadly neutralizing antibodies for HIV prevention - a funders perspective (not available)
S. Becker
FDA perspective
K. Struble
State of the art lecture on treatment challenges for HIV/HCV coinfected patients
M. Sulkowski
Defining the therapeutic range of ribavirin in the era of DAA-telaprevir based triple therapy for HCV infection: is it possible?
K. de Kanter
ITPA activity and Ribavirin Ctrough are both predictive of ribavirin-induced anemia in HIV-HCV patients receiving boceprevir-based triple therapy (ANRS HC27)
C. Solas
Drug interactions between direct acting anti-HCV antivirals Sofosbuvir and Ledipasvir and HIV antiretrovirals
P. German
Evaluation of transporter and cytochrome P450-mediated drug-drug interactions between pan-genotypic HCV NS5A inhibitor GS-5816 and phenotypic probe drugs
E. Mogalian
Clinical Case presentation
J. Rockstroh
Renal transporters (not available)
K. Giacomini
FDA perspective (not available)
V. Arya
FDA perspective on PBPK
Use of mechanistic PBPK modeling to predict the potential for renal transporter DDIs between Dolutegravir-Tenofovir & Dolutegravir-Metformin
G. Generaux
The use of PBPK to characterize the interplay between metabolism and transport in the disposition of simeprevir in healthy volunteers and HCV infected patients.
S. Ouwerkerk-Mahadevan
The role of PK/PD tissue models for Prevention (not available)
L. Rohan
Mucosal tissue pharmacokinetics of maraviroc and raltegravir in women: implications for chemoprophylaxis.
M. Cottrell
A multi-compartment single and multiple dose pharmacokinetic comparison of rectally applied tenofovir 1% gel and oral tenofovir disoproxil fumarate
K-H. Yang
Estimated onset and duration of PrEP activity for daily TDF/FTC using the EC90 from iPrEx
S. Seifert
Population analysis of Tenofovir plasma and intracellular pharmacokinetics in female HIV-1 seropositive patients (not available)
K. Larson
Simulation of the interaction between erlotinib and ritonavir using a physiologically based pharmacokinetic model
J. Molto
Pharmacokinetic of raltegravir (800 mg) once-daily in switching strategies in HIV-1-infected patients with suppressed viremia
G. Peytavin
Age and gender effects on the pharmacokinetics of HCV NS5A inhibitor MK-8742
W. Yeh
Plasma concentrations of the novel HCV entry inhibitor, ITX 5061, in liver transplant patients
C. Venuto
Population pharmacokinetics of tenofovir-diphosphate in red blood cells in HIV-negative and HIV-infected adults.
J. Castillo-Mancilla
Bristol-Myers Squibb HCV DAAs: Review of Interactions Involving Transporters
T. Eley
Abbvie: Drug interactions with AbbVie HCV DAAs
R. Menon
Gilead: Transporters: role in clinical development of HCV compounds
B. Kirby
DDIs in the evolving HCV treatment landscape (session supported by AbbVie)(not available)
Case-Based DDI: Oncology
A. Tseng
Case-Based DDI: Transplantation
Translational studies to understand the mechanism of liver delivery by Sofosbuvir(not available)
A. Ray
A novel microdose approach to assess bioavailability, intestinal absorption, gut metabolism and hepatic clearance of simeprevir in healthy volunteers
S. Ouwerkerk-Mahadevan
Towards physiologically-based pharmacokinetic modelling of darunavir/ritonavir in pregnancy
A. Colbers
Total and unbound pharmacokinetics of once-daily darunavir/ritonavir in HIV-1–infected pregnant women
H. Crauwels
Large scale utilisation of dried blood spots (DBS) for the characterisation of efavirenz (EFV) pharmacokinetics (PK) in the ENCORE 1 study
L. Else